Lifeboat Foundation: Safeguarding Humanity
Toggle light / dark theme

Blog

Category: biotech/medical – Page 1,315

ISM001-055 demonstrated highly promising results in multiple preclinical studies including in vitro biological studies, pharmacokinetic and safety studies. The compound significantly improved myofibroblast activation which contributes to the development of fibrosis. ISM001-055’s novel target is potentially relevant to a broad range of fibrotic indications.

“We are very pleased to see Insilico Medicine’s first antifibrotic drug candidate entering into the clinic,” said Feng Ren 0, PhD, CSO of Insilico Medicine. “We believe this is a significant milestone in the history of AI-powered drug discovery because to our knowledge the drug candidate is the first ever AI-discovered novel molecule based on an AI-discovered novel target. We have leveraged our end-to-end AI-powered drug discovery platform, including the usage of generative biology and generative chemistry, to discover novel biological targets and generate novel molecules with drug-like properties. ISM001-055 is the first such compound to enter the clinic, and we expect more to come in the near future [1].”

Previously, Insilico Medicine demonstrated its ability to generate drug-like hit molecules using AI with the publication of the Generative Tensorial Reinforcement Learning (GENTRL) system for a well-known target in record time [2]. It also demonstrated the target’s proof of concept by applying deep learning techniques for the identification of novel biological targets. This novel antifibrotic program combined these target discovery and generative chemistry capabilities. Notably, Insilico Medicine completed the entire discovery process from target discovery to preclinical candidate nomination within 18 months on a budget of $2.6 million.

Read more | >

Scientists in California tried to study Alzheimer’s disease from a different perspective and the results may have led them to the cause of the disease.

Researchers at the University of California-Riverside (UCR) recently published results from a study that looked at a protein called tau. By studying the different forms tau proteins take, researchers discovered the difference between people who developed dementia and those who didn’t.

The tau protein was critical for researchers because they wanted to understand what the protein could reveal about the mechanism behind plaques and tangles, two critical indicators doctors look for when diagnosing people with Alzheimer’s.

Read more | >

The race to find medical treatments for Covid-19—and future pandemics—is on, driving renewed investments by the healthcare and pharmaceutical industries in Real-World Data (RWD) and Real-World Evidence (RWE). A new report on AI and the real-world studies industry, from Deep Pharma Intelligence (DPI), Evomics Medical and The Yuan (an online forum focused on AI in healthcare, for which I am a contributor), provides fresh insights into this rapidly evolving patient-centric approach to increasing R&D efficiency, accelerating the introduction of new drugs, and improving health outcomes. Full Story:

Read more | >

Circa 2019

Researchers of Sechenov University and University of Pittsburgh described the most promising strategies in applying genetic engineering for studying and treating Parkinson’s disease. This method can help evaluate the role of various cellular processes in pathology progression, develop new drugs and therapies, and estimate their efficacy using animal disease models. The study was published in Free Radical Biology and Medicine.

Parkinson’s disease is a neurodegenerative disorder accompanied by a wide array of motor and cognitive impairments. It develops mostly among elderly people (after the age of 55–60). Parkinson’s symptoms usually begin gradually and get worse over time. As the disease progresses, people may have difficulty controlling their movements, walking and talking and, more importantly, taking care of themselves. Although there is no cure for Parkinson’s disease, medicines, surgical treatment, and other therapies can often relieve some symptoms.

The disease is characterized by significant (up to 50–70%) loss of dopaminergic neurons, i.e. nerve cells that synthesize neurotransmitter dopamine which enables communication between the neurons. Another hallmark is the presence of Lewy bodies — oligomeric deposits of a protein called alpha-synuclein inside the neurons.

Continue reading “Scientists listed ways of applying genetic engineering to treat Parkinson’s disease” | >

Citizen journalist now close to death.

Citizen journalist Zhang Zhan is in a Chinese prison for reporting from Wuhan during the height of the city’s coronavirus outbreak in 2020. Her family says she is on hunger strike and could be near death. All calls for her release have gone unheeded.

“Zhang Zhan distributed independent information on what happened in Wuhan,” the managing director of Reporters Without Borders Germany, Christian Mihr, told DW. He asked Germany and the EU to be more outspoken ahead of the 2022 Winter Olympics in Beijing.

Continue reading “China: Citizen journalist Zhang Zhan detained over Wuhan reporting | DW News” | >

Researchers have developed a new approach to machine learning that ‘learns how to learn’ and out-performs current machine learning methods for drug design, which in turn could accelerate the search for new disease treatments.

The method, called transformational machine learning (TML), was developed by a team from the UK, Sweden, India and Netherlands. It learns from multiple problems and improves performance while it learns.

TML could accelerate the identification and production of new drugs by improving the machine learning systems which are used to identify them. The results are reported in the Proceedings of the National Academy of Sciences.

Read more | >

There’s also been a lot of interest in creating more versatile “living inks” made up of bacteria, which can be genetically engineered to do everything from deliver drugs to clean up pollutants. But so far, approaches have relied on mixing microbes with polymers that help provide the ink with some structural integrity.

Now, researchers have developed a new living ink that more closely lives up to the name by replacing the polymers with a protein made by genetically engineered E. coli bacteria. The researchers say this opens the door to seeding large-scale, living structures from nothing more than a simple cell culture.

The key to the breakthrough was to repurpose the proteins that E. coli cells secrete to stick together and form hard-to-shift biofilms. In a paper in Nature Communications, the researchers describe how they genetically engineered bacteria to produce two different versions of this protein known as a “knob” and a “hole,” which then lock together to form a robust cross-linked mesh.

Read more | >

TRU Community Care in Lafayette was the host to the unveiling of a brand new technology in the medical field — a humanoid robot that can perform basic medical tasks.

Beyond Imagination, an AI company based out of Colorado Springs, visited the Lafayette hospice center to test out the robot, named BEOMNI.

“We are excited that TRU sees the almost limitless potential of our humanoid robots in health care and has agreed to run this first pilot study with us. We look forward to partnering with them to bring a highly effective solution to market,” said inventor and CEO Dr. Harry Kloor.

Read more | >

The mysterious ways cancer spreads through the body, a process known as metastasis, is what can make it such a difficult enemy to keep at bay. Researchers at Princeton University working in this area have been tugging at a particular thread for more than 15 years, focusing on a single gene central to the ability of most major cancers to metastasize. They’ve now discovered what they describe as a “silver bullet” in the form of a compound that can disable this gene in mice and human tissue, with clinical trials possibly not too far away.

Metastatic cancer is a key focus for researchers and with good reason, as it is actually the primary cause of death from the disease. While surgery or chemotherapy might be effective at eliminating an initial tumor, cells that have broken away can discreetly make their way around the body and give rise to new tumors, months or even years later.

“Metastatic breast cancer causes more than 40,000 deaths every year in the US, and the patients do not respond well to standard treatments, such as chemotherapies, targeted therapies and immunotherapies,” says Minhong Shen, member of the Princeton team behind the new discovery. “Our work identified a series of chemical compounds that could significantly enhance the chemotherapy and immunotherapy response rates in metastatic breast cancer mouse models. These compounds have great therapeutic potential.”

Read more | >